{
    "hands_on_practices": [
        {
            "introduction": "Serologic testing is fundamental to the diagnosis of Lyme borreliosis, but its effectiveness is critically dependent on timing. This exercise explores how the performance of the standard two-tier testing algorithm changes during the early stages of infection, a direct consequence of the patient's evolving immune response. By calculating the overall sensitivity and specificity at different time points, you will gain a quantitative understanding of the 'seronegative window' in early disease and appreciate why clinical diagnosis remains paramount .",
            "id": "4413409",
            "problem": "A clinician is evaluating serologic testing for early localized Lyme disease in patients with erythema migrans after an Ixodes tick bite. The practice uses traditional two-tier serology: an initial enzyme-linked immunosorbent assay (ELISA) followed by a confirmatory Western blot (WB). The overall two-tier result is defined as positive only if both the first-tier and second-tier tests are positive; if the first-tier test is negative, no second-tier test is performed and the overall result is negative. Assume conditional independence of test results given true infection status and day from illness onset. Also assume that specificity in non-diseased individuals is stable across early time points.\n\nYou are given stage-specific performance characteristics for each tier in early localized disease:\n\n- At day $7$ after illness onset: ELISA sensitivity $0.35$, ELISA specificity $0.97$; WB sensitivity $0.55$, WB specificity $0.99$.\n- At day $30$ after illness onset: ELISA sensitivity $0.88$, ELISA specificity $0.97$; WB sensitivity $0.82$, WB specificity $0.99$.\n\nUsing only the definitions of sensitivity and specificity and basic probability rules, compute the expected overall sensitivity and specificity of the two-tier algorithm at day $7$ and at day $30$ after illness onset. Then, based on these values, interpret what they imply for ruling in versus ruling out early localized Lyme disease at day $7$ compared with day $30$.\n\nReport your numerical answers for the four requested quantities in the order: day $7$ sensitivity, day $7$ specificity, day $30$ sensitivity, day $30$ specificity. Express each as a decimal and round each to four significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in the principles of diagnostic test evaluation, is mathematically well-posed, and uses objective, precise language. All necessary data and assumptions for a unique solution are provided.\n\nFirst, we define the relevant events and parameters based on the problem statement.\nLet $D$ be the event that a patient has Lyme disease.\nLet $D^c$ be the event that a patient does not have Lyme disease.\nLet $T_E^+$ and $T_E^-$ be the events of a positive and negative enzyme-linked immunosorbent assay (ELISA) test, respectively.\nLet $T_W^+$ and $T_W^-$ be the events of a positive and negative Western blot (WB) test, respectively.\nLet $T_{overall}^+$ and $T_{overall}^-$ be the events of a positive and negative overall two-tier test result.\n\nThe sensitivity ($Se$) of a test is the probability of a positive test result given that the disease is present: $Se = P(T^+|D)$.\nThe specificity ($Sp$) of a test is the probability of a negative test result given that the disease is absent: $Sp = P(T^-|D^c)$.\n\nThe two-tier algorithm is defined as follows:\nAn overall positive result, $T_{overall}^+$, occurs only if the ELISA is positive and the confirmatory WB is also positive.\n$$T_{overall}^+ = T_E^+ \\cap T_W^+$$\nAn overall negative result, $T_{overall}^-$, occurs if the ELISA is negative (in which case the WB is not performed) or if the ELISA is positive but the WB is negative.\n$$T_{overall}^- = T_E^- \\cup (T_E^+ \\cap T_W^-)$$\n\nWe can now derive the general formulas for the overall sensitivity and specificity of the two-tier algorithm.\n\n**Overall Sensitivity ($Se_{overall}$)**\nThe overall sensitivity is the probability of an overall positive test result in a patient with the disease.\n$$Se_{overall} = P(T_{overall}^+ | D) = P(T_E^+ \\cap T_W^+ | D)$$\nThe problem states to assume conditional independence of test results given the true infection status. Therefore, the probability of both tests being positive in a diseased patient is the product of their individual probabilities.\n$$P(T_E^+ \\cap T_W^+ | D) = P(T_E^+ | D) \\times P(T_W^+ | D)$$\nBy definition, $P(T_E^+ | D)$ is the sensitivity of the ELISA ($Se_E$) and $P(T_W^+ | D)$ is the sensitivity of the WB ($Se_W$).\n$$Se_{overall} = Se_E \\times Se_W$$\n\n**Overall Specificity ($Sp_{overall}$)**\nThe overall specificity is the probability of an overall negative test result in a patient without the disease.\n$$Sp_{overall} = P(T_{overall}^- | D^c)$$\nAn alternative and simpler approach is to calculate the overall false-positive rate ($FPR_{overall}$) and use the relation $Sp_{overall} = 1 - FPR_{overall}$. The overall false-positive rate is the probability of an overall positive result in a patient without the disease.\n$$FPR_{overall} = P(T_{overall}^+ | D^c) = P(T_E^+ \\cap T_W^+ | D^c)$$\nUsing conditional independence for non-diseased individuals:\n$$P(T_E^+ \\cap T_W^+ | D^c) = P(T_E^+ | D^c) \\times P(T_W^+ | D^c)$$\nWe know that $P(T_E^+ | D^c) = 1 - P(T_E^- | D^c) = 1 - Sp_E$, which is the false-positive rate of the ELISA. Similarly, $P(T_W^+ | D^c) = 1 - Sp_W$.\nTherefore:\n$$FPR_{overall} = (1 - Sp_E) \\times (1 - Sp_W)$$\nAnd the overall specificity is:\n$$Sp_{overall} = 1 - FPR_{overall} = 1 - (1 - Sp_E)(1 - Sp_W)$$\n\nNow, we apply these formulas to the data provided for day $7$ and day $30$.\n\n**Calculations for Day 7**\nGiven values:\n$Se_{E,7} = 0.35$\n$Sp_{E,7} = 0.97$\n$Se_{W,7} = 0.55$\n$Sp_{W,7} = 0.99$\n\nOverall sensitivity at day $7$:\n$$Se_{overall, 7} = Se_{E,7} \\times Se_{W,7} = 0.35 \\times 0.55 = 0.1925$$\n\nOverall specificity at day $7$:\n$$Sp_{overall, 7} = 1 - (1 - Sp_{E,7})(1 - Sp_{W,7}) = 1 - (1 - 0.97)(1 - 0.99)$$\n$$Sp_{overall, 7} = 1 - (0.03)(0.01) = 1 - 0.0003 = 0.9997$$\n\n**Calculations for Day 30**\nGiven values:\n$Se_{E,30} = 0.88$\n$Sp_{E,30} = 0.97$\n$Se_{W,30} = 0.82$\n$Sp_{W,30} = 0.99$\n\nOverall sensitivity at day $30$:\n$$Se_{overall, 30} = Se_{E,30} \\times Se_{W,30} = 0.88 \\times 0.82 = 0.7216$$\n\nOverall specificity at day $30$:\nThe specificities of the individual tests are the same as on day $7$.\n$$Sp_{overall, 30} = 1 - (1 - Sp_{E,30})(1 - Sp_{W,30}) = 1 - (1 - 0.97)(1 - 0.99)$$\n$$Sp_{overall, 30} = 1 - (0.03)(0.01) = 1 - 0.0003 = 0.9997$$\n\nThe four requested numerical quantities, rounded to four significant figures, are:\nDay $7$ sensitivity: $0.1925$\nDay $7$ specificity: $0.9997$\nDay $30$ sensitivity: $0.7216$\nDay $30$ specificity: $0.9997$\n\n**Interpretation**\nThe utility of a diagnostic test is often summarized by its ability to \"rule in\" or \"rule out\" a disease.\nA test with high specificity is good for **ruling in** a disease. A positive result from such a test makes the diagnosis very likely, as false positives are rare.\nA test with high sensitivity is good for **ruling out** a disease. A negative result from such a test makes the diagnosis very unlikely, as false negatives are rare.\n\nAt both day $7$ and day $30$, the overall specificity of the two-tier algorithm is exceptionally high ($Sp_{overall} = 0.9997$). This implies a very low false-positive rate ($1 - 0.9997 = 0.0003$). Consequently, a positive test result at either time point is a very strong indicator that the patient has Lyme disease. The algorithm is excellent for **ruling in** (confirming) the disease at both early and later stages.\n\nThe overall sensitivity, however, changes dramatically.\nAt day $7$, the sensitivity is very low ($Se_{overall, 7} = 0.1925$). This means the test will fail to detect the disease in approximately $1 - 0.1925 = 80.75\\%$ of infected patients. A negative result at this early stage is therefore not meaningful for **ruling out** the disease. A clinician cannot be confident that a patient with a negative test at day $7$ is truly free of the disease.\n\nAt day $30$, the sensitivity has improved substantially to a moderate level ($Se_{overall, 30} = 0.7216$). The test now correctly identifies about $72\\%$ of infected patients. While it is much better than at day $7$, it still produces a false-negative result in about $1-0.7216 = 27.84\\%$ of cases. Thus, while a negative result at day $30$ makes Lyme disease less likely, it is not definitive for **ruling out** the disease, especially if strong clinical signs (like erythema migrans) are present.\n\nIn summary, the two-tier testing algorithm is highly effective for confirming a diagnosis of Lyme disease at any point, but it is unreliable for ruling out the disease in the very early stage (day $7$). Its ability to rule out improves by day $30$ but remains imperfect. This highlights the clinical principle that serologic testing for early Lyme disease should be interpreted with caution, and a negative result, particularly early on, does not exclude the diagnosis.",
            "answer": "$$ \\boxed{ \\begin{pmatrix} 0.1925 & 0.9997 & 0.7216 & 0.9997 \\end{pmatrix} } $$"
        },
        {
            "introduction": "A diagnostic test's intrinsic sensitivity and specificity are only half the story; its true clinical utility is measured by its predictive value in a specific population. This practice applies Bayes' theorem to calculate the positive predictive value ($PPV$) of a modern Lyme disease testing algorithm in a high-risk clinical cohort . This exercise will solidify your understanding of how pre-test probability, or disease prevalence, critically influences the interpretation of a positive test result.",
            "id": "4413415",
            "problem": "In a tertiary dermatology clinic serving an endemic region for Lyme borreliosis, clinicians evaluate patients presenting with annular erythema after recent tick exposure. A Modified Two-Tier Testing (MTTT) algorithm for Lyme disease is used as a single composite diagnostic test, and its performance characteristics in this clinical cohort are well validated: the test has sensitivity $0.90$ and specificity $0.95$. The cohort under evaluation has a disease prevalence (pretest probability) of $0.10$ for early Lyme borreliosis among those tested.\n\nUsing only the core definitions of sensitivity, specificity, and disease prevalence together with Bayes’ theorem, derive and compute the positive predictive value, defined as $P(\\text{Disease} \\mid \\text{Test positive})$, of this MTTT algorithm in this cohort. Express your final answer as an exact fraction (no rounding), and do not use a percent sign. The final answer must be a single number without any units.",
            "solution": "The problem statement is subjected to a rigorous validation process before any attempt at a solution.\n\n### Step 1: Extract Givens\nThe problem provides the following data and definitions for a specific clinical cohort and diagnostic test:\n-   A Modified Two-Tier Testing (MTTT) algorithm is used as a single composite diagnostic test.\n-   Sensitivity of the test: $S_e = 0.90$.\n-   Specificity of the test: $S_p = 0.95$.\n-   Prevalence of early Lyme borreliosis in the cohort (pre-test probability): $P(\\text{Disease}) = 0.10$.\n-   The quantity to be derived and computed is the positive predictive value (PPV), defined as $P(\\text{Disease} \\mid \\text{Test positive})$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for validity based on the established criteria.\n-   **Scientifically Grounded**: The problem is well-grounded in the fields of biostatistics and epidemiology. The concepts of sensitivity, specificity, prevalence, and positive predictive value are fundamental to the evaluation of diagnostic tests. The scenario described—evaluating patients for Lyme disease in an endemic area using a standard testing algorithm—is clinically realistic. The given numerical values for sensitivity, specificity, and prevalence are plausible.\n-   **Well-Posed**: The problem is clearly defined. It provides all necessary information to calculate a unique solution for the positive predictive value. The objective is explicitly stated.\n-   **Objective**: The problem is stated in precise, objective language, free of ambiguity or subjective claims.\n-   **Completeness**: The problem is self-contained and does not lack any essential data required for the application of Bayes' theorem.\n-   **Consistency**: The givens are numerically and conceptually consistent. There are no contradictions.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is a standard, well-posed problem in applied probability. The solution process will now proceed.\n\n### Solution Derivation\nThe objective is to compute the positive predictive value (PPV) of the MTTT algorithm for Lyme borreliosis in the specified cohort. The PPV is the conditional probability that a patient has the disease given that they have tested positive.\n\nLet $D$ be the event that a patient has the disease, and let $D^c$ be the complement event, that the patient does not have the disease.\nLet $T^+$ be the event that the test result is positive, and let $T^-$ be the complement event, that the test result is negative.\n\nThe information provided can be formulated in the language of conditional probability:\n1.  The prevalence, or prior probability of disease, is $P(D) = 0.10$.\n2.  The probability of not having the disease is the complement of the prevalence: $P(D^c) = 1 - P(D) = 1 - 0.10 = 0.90$.\n3.  The sensitivity is the probability of a positive test given the presence of disease: $P(T^+ \\mid D) = 0.90$. This is the true positive rate.\n4.  The specificity is the probability of a negative test given the absence of disease: $P(T^- \\mid D^c) = 0.95$. This is the true negative rate.\n\nFrom the specificity, we can determine the false positive rate, which is the probability of a positive test given the absence of disease:\n$$ P(T^+ \\mid D^c) = 1 - P(T^- \\mid D^c) = 1 - 0.95 = 0.05 $$\n\nThe goal is to find the positive predictive value, which is expressed as $P(D \\mid T^+)$. According to Bayes' theorem, this posterior probability is given by:\n$$ P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+)} $$\n\nThe term in the denominator, $P(T^+)$, is the total probability of obtaining a positive test result. It can be calculated using the law of total probability by summing the probabilities of the two disjoint events that result in a positive test: a true positive and a false positive.\n$$ P(T^+) = P(T^+ \\cap D) + P(T^+ \\cap D^c) $$\nUsing the definition of conditional probability, $P(A \\cap B) = P(A \\mid B)P(B)$, we can expand this to:\n$$ P(T^+) = P(T^+ \\mid D) P(D) + P(T^+ \\mid D^c) P(D^c) $$\n\nNow, we substitute the known values into this expression to compute $P(T^+)$:\n$$ P(T^+) = (0.90)(0.10) + (0.05)(0.90) $$\n$$ P(T^+) = 0.090 + 0.045 $$\n$$ P(T^+) = 0.135 $$\n\nWith $P(T^+)$ calculated, we can return to Bayes' theorem to find the PPV, $P(D \\mid T^+)$. The numerator, $P(T^+ \\mid D) P(D)$, is the probability of a true positive, which we already calculated as part of the total probability:\n$$ P(T^+ \\mid D) P(D) = (0.90)(0.10) = 0.09 $$\n\nTherefore, the positive predictive value is:\n$$ P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+)} = \\frac{0.09}{0.135} $$\n\nThe problem requires the answer to be expressed as an exact fraction. To simplify the fraction $\\frac{0.09}{0.135}$, we can multiply the numerator and denominator by $1000$ to work with integers:\n$$ \\frac{0.09}{0.135} = \\frac{90}{135} $$\nTo simplify this fraction, we find the greatest common divisor of $90$ and $135$.\nThe prime factorization of $90$ is $2 \\times 3^2 \\times 5$.\nThe prime factorization of $135$ is $3^3 \\times 5$.\nThe greatest common divisor is $3^2 \\times 5 = 45$.\nDividing the numerator and denominator by $45$:\n$$ \\frac{90 \\div 45}{135 \\div 45} = \\frac{2}{3} $$\n\nThus, the positive predictive value of the MTTT algorithm in this cohort is $\\frac{2}{3}$.",
            "answer": "$$\\boxed{\\frac{2}{3}}$$"
        },
        {
            "introduction": "In managing potentially fatal infections like Rocky Mountain spotted fever (RMSF), the decision to treat empirically is one of the most critical judgments a clinician can make. This decision must be made under profound uncertainty, balancing the risk of untreated disease against the risks of treatment itself. This hands-on practice guides you through a formal decision analysis to derive the treatment threshold probability—the level of clinical suspicion above which empiric therapy becomes the optimal strategy to minimize harm .",
            "id": "4413429",
            "problem": "A dermatologist is consulted by an emergency department for a patient with a suspected tick-borne dermatosis consistent with Rocky Mountain spotted fever (RMSF). Because clinical features of RMSF and other arthropod bite reactions can overlap early, the dermatologist considers empiric doxycycline. Assume the following well-tested and widely accepted decision-analytic bases: expected value maximization using Bernoulli utilities that assign a disutility of $1$ to any serious harm (including death) and $0$ otherwise, linearity of expectation, independence of treatment adverse events from disease status, and that empiric therapy affects outcomes only if RMSF is actually present. Let $p$ denote the clinician’s pre-test probability that the patient truly has RMSF.\n\nSuppose the untreated case-fatality risk of RMSF is $5\\%$, empiric doxycycline reduces RMSF mortality by $90\\%$ (relative risk reduction among those who truly have RMSF), and the risk of a serious drug-related adverse event from doxycycline is $0.1\\%$ for any treated patient. Model the decision between “treat empirically now” versus “do not treat empirically” as a comparison of expected disutilities of serious harm.\n\nDerive, from first principles and the stated bases, the threshold value $p^{\\ast}$ at which the expected disutility of serious harm is equal between empiric treatment and no empiric treatment, and compute its numerical value. Express the threshold probability as a decimal fraction rounded to four significant figures.",
            "solution": "The problem asks for the derivation of a threshold probability, $p^{\\ast}$, for empiric treatment in a case of suspected Rocky Mountain spotted fever (RMSF). The decision is to be based on minimizing the expected disutility of serious harm.\n\nFirst, we must validate the problem statement.\n\n**Step 1: Extract Givens**\n- Decision framework: Expected value maximization with Bernoulli utilities.\n- Disutility of any serious harm: $1$.\n- Disutility of no serious harm: $0$.\n- Assumption: Linearity of expectation.\n- Assumption: Independence of treatment adverse events from disease status.\n- Assumption: Empiric therapy affects outcomes only if RMSF is actually present.\n- $p$: Pre-test probability that the patient has RMSF.\n- Untreated case-fatality risk of RMSF: $5\\%$.\n- Relative risk reduction of RMSF mortality with doxycycline: $90\\%$.\n- Risk of a serious drug-related adverse event from doxycycline: $0.1\\%$.\n- Task: Derive the threshold value $p^{\\ast}$ where the expected disutility of serious harm is equal for both actions: \"treat empirically\" and \"do not treat empirically\".\n- Task: Compute the numerical value of $p^{\\ast}$ rounded to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using a standard decision-analytic model common in medical economics and clinical epidemiology. The clinical scenario is realistic, and the provided parameters are plausible for a hypothetical case. The problem is well-posed, providing all necessary data and assumptions (e.g., utility values, probabilities, independence) to formulate and solve for a unique threshold probability. The language is objective and precise. The problem does not violate any of the invalidity criteria. It is a formalizable, self-contained, and non-trivial problem in applied probability.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be provided.\n\n**Derivation of the Threshold Probability**\n\nLet $p$ be the probability that the patient has RMSF, denoted as event $R$. The probability that the patient does not have RMSF, event $R^c$, is $1-p$. The decision framework uses disutility, where a serious harm event has a disutility of $1$ and no harm has a disutility of $0$. Therefore, the expected disutility of an action is equal to the total probability of serious harm associated with that action. We seek the threshold probability $p^{\\ast}$ at which the expected disutilities of the two actions are equal.\n\nLet the two actions be $A_T$ (treat empirically) and $A_{NT}$ (do not treat empirically). We must find $p^{\\ast}$ such that $E[D(A_T)] = E[D(A_{NT})]$, where $D$ denotes disutility.\n\n**Expected Disutility of \"Do Not Treat\" ($E[D(A_{NT})]$)**\nIf we do not treat, the only potential for serious harm is death from RMSF, which occurs only if the patient has the disease.\n- The untreated case-fatality risk of RMSF is given as $c_{ut} = 0.05$. This is the conditional probability of death given RMSF and no treatment, $P(\\text{Harm}|R, A_{NT})$.\n- If the patient does not have RMSF, there is no disease and no treatment, so the probability of harm is $0$, i.e., $P(\\text{Harm}|R^c, A_{NT}) = 0$.\n\nUsing the law of total probability, the expected disutility is:\n$$E[D(A_{NT})] = P(\\text{Harm}|A_{NT}) = P(\\text{Harm}|R, A_{NT})P(R) + P(\\text{Harm}|R^c, A_{NT})P(R^c)$$\n$$E[D(A_{NT})] = c_{ut} \\cdot p + 0 \\cdot (1-p) = 0.05p$$\n\n**Expected Disutility of \"Treat Empirically\" ($E[D(A_T)]$)**\nIf we treat, serious harm can arise from two sources: death from RMSF despite treatment, or a serious adverse event from the drug. Let $H_D$ be the event of harm from disease (death) and $H_{drug}$ be the event of harm from the drug. The disutility is $1$ if *any* harm occurs, so we are interested in the probability of the union of these events, $P(H_D \\cup H_{drug})$.\n\nLet's define the relevant probabilities:\n- The risk of a serious drug-related adverse event is $r_{drug} = 0.001$. The problem states this is independent of disease status, so $P(H_{drug}|A_T) = r_{drug}$.\n- The untreated case-fatality risk is $c_{ut} = 0.05$.\n- Treatment provides a relative risk reduction ($RRR$) of $0.90$.\n- The relative risk ($RR$) is $1 - RRR = 1 - 0.90 = 0.10$.\n- The treated case-fatality risk, $c_t$, is the untreated risk multiplied by the relative risk:\n$$c_t = c_{ut} \\times RR = 0.05 \\times 0.10 = 0.005$$\nThis is the conditional probability of death from RMSF given that the patient has RMSF and is treated, $P(H_D|R, A_T)$.\n\nThe expected disutility of treatment is the total probability of harm, which we calculate using the law of total probability, conditioning on the patient's disease status:\n$$E[D(A_T)] = P(\\text{Harm}|A_T) = P(\\text{Harm}|R, A_T)P(R) + P(\\text{Harm}|R^c, A_T)P(R^c)$$\n\n- If the patient has RMSF (with probability $p$), harm can occur from the disease or the drug. The probability of harm is $P(H_D \\cup H_{drug} | R, A_T)$. Assuming the events are independent, as is standard in such models unless specified otherwise:\n$$P(\\text{Harm}|R, A_T) = P(H_D|R, A_T) + P(H_{drug}|R, A_T) - P(H_D|R, A_T)P(H_{drug}|R, A_T)$$\n$$P(\\text{Harm}|R, A_T) = c_t + r_{drug} - c_t \\cdot r_{drug}$$\n$$P(\\text{Harm}|R, A_T) = 0.005 + 0.001 - (0.005)(0.001) = 0.006 - 0.000005 = 0.005995$$\n\n- If the patient does not have RMSF (with probability $1-p$), the only source of harm is the drug. The problem states therapy affects outcomes only if RMSF is present, which applies to disease outcome, not drug side effects.\n$$P(\\text{Harm}|R^c, A_T) = P(H_{drug}|R^c, A_T) = r_{drug} = 0.001$$\n\nNow, we assemble the expression for $E[D(A_T)]$:\n$$E[D(A_T)] = (c_t + r_{drug} - c_t \\cdot r_{drug}) \\cdot p + r_{drug} \\cdot (1-p)$$\n$$E[D(A_T)] = (0.005995)p + 0.001(1-p)$$\n$$E[D(A_T)] = 0.005995p + 0.001 - 0.001p$$\n$$E[D(A_T)] = 0.004995p + 0.001$$\n\n**Solving for the Threshold $p^{\\ast}$**\nWe set the expected disutilities equal to find the threshold probability $p^{\\ast}$:\n$$E[D(A_{NT})] = E[D(A_T)]$$\n$$0.05p^{\\ast} = 0.004995p^{\\ast} + 0.001$$\nTo solve for $p^{\\ast}$, we gather the terms involving $p^{\\ast}$:\n$$0.05p^{\\ast} - 0.004995p^{\\ast} = 0.001$$\n$$p^{\\ast}(0.05 - 0.004995) = 0.001$$\n$$p^{\\ast}(0.045005) = 0.001$$\n$$p^{\\ast} = \\frac{0.001}{0.045005}$$\n\n**Numerical Computation**\n$$p^{\\ast} \\approx 0.022219753...$$\nThe problem requires the answer to be a decimal fraction rounded to four significant figures.\n$$p^{\\ast} \\approx 0.02222$$\nThis threshold means that if the clinician's suspicion (pre-test probability) of RMSF is greater than approximately $2.222\\%$, the expected disutility of serious harm is lower with empiric treatment than without it.",
            "answer": "$$\\boxed{0.02222}$$"
        }
    ]
}